mavrilimumab   Click here for help

GtoPdb Ligand ID: 7785

Synonyms: CAM-3001 | KPL-301
Immunopharmacology Ligand
Compound class: Antibody
Comment: Mavrilimumab targets CSF2RA (aka GM-CSFRα).
Peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis identifies mavrilimumab as antibody 6 in patent US8263075 [2].
Click here for help
Immunopharmacology Comments
Phase 2 trial results from RA patients were published in 2018 [1] which showed that the effective response to mavrilimumab therapy was maintained long-term (at 122 weeks), and that it was well-tolerated. The development program on mavrilimumab in RA has since been discontinued, but development remains active in GCA.
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Clinical candidate therapeutic for RA (Phase 2 studies completed).
Temporal arteritis Disease Ontology: DOID:13375
OMIM: 187360
Orphanet: ORPHA397
Mavrilimumab is a Phase 2 clinical candidate for temporal arteritis (giant cell arteritis).